Novo Nordisk, FDA and Wegovy

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resol
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
FDA declares Wegovy and Ozempic shortage over, Novo Nordisk confirms
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The
US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi

Eli Lilly, drug

Reuters16d
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Novo lost out to Lilly in the fourth quarter in terms of total weekly prescriptions written for Wegovy compared to Lilly's Zepbound in the United States, the biggest market. Novo is looking for ...
Super Bowl ad sparks controversy over cut-rate Wegovy alternative
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Reuters16d
Lilly needs a plan to spur weight-loss drug sales, investors say
One investor and three analysts told Reuters they expect Lilly to share details on how it plans to promote Zepbound this year in a bid to take more market share from Wegovy, an older, more ...